Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus

JAMA - Journal of the American Medical Association

Volumn 313, Issue 10, 2015, Pages 1029-1036

  Besseling, Joost ^a   Kastelein, John J P ^a   Defesche, Joep C ^a   Hutten, Barbara A ^a   Hovingh, G Kees ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; DNA; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; APOB GENE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE; GENE DELETION; GENE MUTATION; HUMAN; LDLR GENE; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; COMPLICATION; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PANCREAS ISLET BETA CELL; REGISTER; STATISTICAL MODEL;

ADULT; CHOLESTEROL, LDL; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INSULIN-SECRETING CELLS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; NETHERLANDS; PREVALENCE; RECEPTORS, LDL; REGISTRIES;

EID: 84924358878     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.1206     Document Type: Article

References (37)

1. Hovingh GK, Davidson MH, Kastelein JJP, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013;34(13): 962-971.
2. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes. Lancet. 2010;375(9716): 735-742.
3. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al; DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight. Lancet. 2014;385(9965):351-361.
4. Sirtori CR. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Pharmacol Res. 1990;22(5):555-563.
5. Fokkema IFAC, den Dunnen JT, Taschner PEM. LOVD: easy creation of a locus-specific sequence variation database using an "LSDB-in-a-box" approach. Hum Mutat. 2005;26(2):63-68.
6. Bertolini S, Pisciotta L, Rabacchi C, et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis. 2013;227(2):342-348.
7. Humphries SE, Cranston T, AllenM, et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia. J Mol Med (Berl). 2006;84(3):203-214.
8. Alonso R, Mata N, Castillo S, et al; Spanish Familial Hypercholesterolaemia Group. Cardiovascular disease in familial hypercholesterolaemia. Atherosclerosis. 2008; 200(2):315-321.
9. Bertolini S, Cantafora A, AvernaM, et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol. 2000;20 (9):41-52.
10. Cobbaert C, Boerma GJ, Lindemans J. Evaluation of the Cholestech L.D.X. desktop analyser for cholesterol, HDL-cholesterol, and triacylglycerols in heparinized venous blood. Eur J Clin Chem Clin Biochem. 1994;32(5):391-394.
11. FriedewaldWT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18 (6):499-502.
12. Besseling J, Kindt I, Hof M, Kastelein JJP, Hutten BA, Hovingh GK. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease. Atherosclerosis. 2014;233(1):219-223.
13. Fouchier SW, Defesche JC, Umans- EckenhausenMW, Kastelein JP. The molecular basis of familial hypercholesterolemia in the Netherlands. Hum Genet. 2001;109(6):602-615.
14. Lombardi MP, Redeker EJ, Defesche JC, et al. Molecular genetic testing for familial hypercholesterolemia. Clin Genet. 2000;57(2):116-124.
15. Harvey JN, Craney L, Kelly D. Estimation of the prevalence of diagnosed diabetes from primary care and secondary care source data: comparison of record linkage with capture-recapture analysis. J Epidemiol Community Health. 2002;56(1):18-23.
16. Costi M, Dilla T, Reviriego J, Castell C, Goday A. Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation. Acta Diabetol. 2010;47(suppl 1):169-175.
17. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolaemia. In: Scriver CR, Beaudet AL, SlyWS, Valle D, eds. TheMetabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:2863-2913.
18. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J AmColl Cardiol. 2014;63(25 pt b): 2889-2934.
19. Santos CAST, Fiaccone RL, Oliveira NF, et al. Estimating adjusted prevalence ratio in clustered cross-sectional epidemiological data. BMC Med Res Methodol. 2008;8:80.
20. Vohl MC, Gaudet D, Moorjani S, et al. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia. Eur J Clin Invest. 1997;27(5):366-373.
21. Preiss D, Seshasai SRK,Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA. 2011;305 (24):2556-2564.
22. Sattar N, Taskinen M-R. Statins are diabetogenic-myth or reality? Atheroscler Suppl. 2012;13(1):1-10.
23. Axsom K, Berger JS, Schwartzbard AZ. Statins and diabetes: the good, the bad, and the unknown. Curr Atheroscler Rep. 2013;15(2):299.
24. Cnop M, Hannaert JC, Grupping AY, Pipeleers DG. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology. 2002;143(9):3449-3453.
25. RoehrichM-E, Mooser V, Lenain V, et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem. 2003;278(20): 18368-18375.
26. Rütti S, Ehses JA, Sibler RA, et al. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology. 2009; 150(10):4521-4530.
27. OramJF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res. 2001;42(8):1173-1179.
28. Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13(3):340-347.
29. Wijesekara N, Zhang LH, Kang MH, et al. miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes. 2012;61(3):653-658.
30. Vergeer M, Brunham LR, Koetsveld J, et al. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care. 2010;33(4):869-874.
31. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations. Lancet. 2011;378(9786):169-181.
32. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes. Lancet. 2014;383(9922):1068-1083.
33. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes. BMJ. 2011;343:d4169.
34. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes. BMJ. 2011;343:d6898.
35. Salas-Salvadó J, Bulló M, Estruch R, et al. Prevention of diabetes with Mediterranean diets. Ann Intern Med. 2014;160(1):1-10.
36. Van de Lisdonk E, Van den BoschW, Lagro-Janssen A, Schers H. (red). Diseases in the Clinic of the General Practitioner. 5th ed. Maarssen: Elsevier; 2008.
37. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension,myocardial infarction and stroke but not for heart failure. J Clin Epidemiol. 2004;57(10):1096-1103.